Head office

3F #307, 288, Digital-ro, Guro-gu,

Seoul, 08390, Republic of Korea

R&D center

3F #304~307, #314, 288, Digital-ro,

Guro-gu, Seoul, 08390, Republic of Korea

Email

business@ngenebio.com

Tel

02-867-9798

Fax

02-866-9784

R&D

Papers

No Year Subject Journal Link
30 2023

Validation and application of new NGS-based HLAgenotyping to clinical diagnostic practice

HLA.2023;101:496–506 clink
29 2023

Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants

Sci Rep 13, 10478 clink
28 2023

Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors

Cancer Res Treat. 2023;55(2):429-441 clink
27 2022

Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer

in vivo 36 (4) 1903-1910 clink
26 2022

NTRK Fusions in 1113 Solid Tumors in a Single Institution

Diagnostics 2022, 12, 1450. clink
25 2022

Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome

Br J Haematol.2022; 00: 1– 10 clink
24 2022

Clinical Utility of Next-generation Sequencing in Real-world Cases: A Single-institution Study of Nine Cases

In Vivo, 36 (3) 1397-1407 clink
23 2022

Isolated Breast Relapse of Early T-Cell Precursor Acute Lymphoblastic Leukemia after Stem Cell Transplantation: A Pediatric Case and Literature Review

Clin Pediatr Hematol Oncol 2022;29:30-4. clink
22 2022

Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers

Sci Rep 12, 1842 clink
21 2022

Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing‒Based NTRK Fusion Detection in South Korea

Cancer Res Treat. 2022 Feb 10 clink